Technology Spotlight - PathogenDX
Oct 08, 2020 12:50 PM - 1:05 PM
Dr. Katchman leads the research and development of sample preparation and assay development at PathogenDx, a Scottsdale, AZ based company which provides disruptive DNA-based pathogen testing technology and solutions for the cannabis, botanical, food
and agricultural industries.
Previously, Dr. Katchman spent 20 years working with various universities and small companies developing novel nucleic acid and proteomic approaches for biomarker discovery and molecular
diagnostics. This includes the development of plate-based and microarray-based diagnostic systems for use in clinical laboratories and point-of-care diagnostics for Arizona State University, FlexBioTech, Inc., and Eccrine Systems, Inc.
Prior to joining PathogenDx, Dr. Katchman was a Principle Investigator at Eccrine Systems, Inc. where he led all
clinical research, regulatory pathway implementation, assay development, and biomarker studies. He was the
co-founder of FlexBioTech, Inc., where he led the development of novel OLED-based molecular diagnostic assay
Dr. Katchman received a B.S. in Microbiology, from Indiana University in 2005, then carried out graduate research with Prof. Douglas F Lake at Arizona State University where he was the first to identify QSOX1 as a proto-oncogene and novel tumor biomarker resulting in over $2M in funding and multiple patents. He
performed his postdoctoral research with Professor Karen S. Anderson and Professor Joshua LaBaer where he designed novel high-density protein microarrays and novel clinical and point of care diagnostics utilizing flexible OLED based electronics resulting in over $15M in funding, multiple patents and high-impact publications.